USE OF CANNABINOIDS IN THE TREATMENT OF COMORBIDITIES ASSOCIATED WITH EPILEPSY

摘要

Cannabidiol (CBD) is disclosed for use in the treatment of quality of life domains associated with epilepsy, preferably treatment resistant epilepsy, wherein the quality of life domain that is treated is one or more of attention/concentration, stigma item, general health, language and social activity and these are improved independent of seizure reduction. Preferably, the CBD is in the form of a highly purified extract of cannabis which comprises at least 98% (w/w) CBD or is present as a synthetic compound. Preferably, the CBD is a highly purified extract which comprises up to 0.1% THC and more preferably up to 1% CDB.